- increased circulating cholesterol level / IMPC
- abnormal auditory brainstem response / IMPC
- increased mean corpuscular volume / IMPC
- decreased circulating unsaturated transferrin level / IMPC
- increased circulating HDL cholesterol level / IMPC
- increased grip strength / IMPC
- increased circulating iron level / IMPC
- abnormal retina blood vessel morphology / IMPC
- decreased locomotor activity / IMPC
B6.Cg-Ldlrtm1Her Tg(APOB*Q2153L)#Boren/Kctt
| Status | Available to order |
| EMMA ID | EM:09689 |
| Citation information | RRID:IMSR_EM:09689 Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information. |
| International strain name | B6.Cg-Ldlrtm1Her Tg(APOB*Q2153L)#Boren/Kctt |
| Alternative name | B6.C57BL/6XSJL-Tg(huB100tm).129S7-Ldlrtm1Her |
| Strain type | Transgenic Strains |
| Allele/Transgene symbol | Tg(APOB*Q2153L)#Boren, Ldlrtm1Her |
| Gene/Transgene symbol | Tg(APOB*Q2153L)#Boren, Ldlr |
Information from provider
| Provider | Jan Borén |
| Provider affiliation | Molecular and Clinical Medicine, University of Gothenburg |
| Additional owner | Göran Hansson, Daniel Ketelhuth and Alexandra Bäcklund, The Cardiovascular Medicine Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden |
| Genetic information | These mice carry the full-length human APOB100 gene, in which codon 2153 has been converted from leucine to glutamine to prevent the formation of ApoB48, generating only ApoB100. They are also deficient in LDLr and have an increased level of LDL-cholesterol, VLDL-cholesterol, and low HDL relative to wild-type mice and develop spontaneous atherosclerosis. |
| Phenotypic information | Homozygous:Mice have hypercholesterolemia and develop spontaneous atherosclerotic lesions. Females have an earlier onset with lesions at 18 weeks compared with males (onset at 26 weeks). Mice are healthy and have no visible effect with a normal life span.Heterozygous:Mice have mild hypercholesterolemia but do not develop spontaneous atherosclerotic lesions. Mice are healthy and have no visible effect with a normal life span. |
| Breeding history | Mice were received at 4 generations backcrossed to C57BL/6J. The mice were then crossed a further 6 generations to C57BL/6J, purchased from JAX Mice in USA. |
| References |
|
| Homozygous fertile | yes |
| Homozygous viable | yes |
| Homozygous matings required | no |
| Immunocompromised | no |
Information from EMMA
| Archiving centre | Karolinska Institutet, Stockholm, Sweden |
| Animals used for archiving | homozygous C57BL/6J males |
Disease and phenotype information
Orphanet associated rare diseases, based on orthologous gene matching
- Homozygous familial hypercholesterolemia / Orphanet_391665
IMPC phenotypes (gene matching)
MGI phenotypes (allele matching)
- increased circulating triglyceride level / MGI
- increased circulating cholesterol level / MGI
- hyperglycemia / MGI
- increased circulating LDL cholesterol level / MGI
- alopecia / MGI
- abnormal liver physiology / MGI
- abnormal adrenal gland morphology / MGI
- scaly skin / MGI
- thick skin / MGI
- increased circulating HDL cholesterol level / MGI
- hepatic steatosis / MGI
- decreased circulating triglyceride level / MGI
- increased cholesterol level / MGI
- increased circulating VLDL cholesterol level / MGI
- atherosclerotic lesions / MGI
- homeostasis/metabolism phenotype / MGI
- increased liver cholesterol level / MGI
- abnormal microglial cell morphology / MGI
- abnormal circulating cholesterol level / MGI
- decreased circulating HDL cholesterol level / MGI
- abnormal triglyceride level / MGI
- abnormal CNS glial cell morphology / MGI
- hyperactivity / MGI
- abnormal spatial learning / MGI
- increased circulating insulin level / MGI
- abnormal astrocyte morphology / MGI
- amyloid beta deposits / MGI
- increased circulating VLDL triglyceride level / MGI
- impaired glucose tolerance / MGI
- abnormal fat pad morphology / MGI
- increased susceptibility to atherosclerosis / MGI
- increased susceptibility to weight gain / MGI
- increased percent body fat/body weight / MGI
- abnormal spatial working memory / MGI
- increased circulating tumor necrosis factor level / MGI
- decreased circulating interleukin-10 level / MGI
- increased circulating interleukin-6 level / MGI
- increased circulating interleukin-1 beta level / MGI
- increased liver triglyceride level / MGI
- increased grip strength / MGI
- decreased susceptibility to weight gain / MGI
- abnormal hippocampus morphology / MGI
- obese / MGI
- increased circulating free fatty acid level / MGI
- liver inflammation / MGI
- abnormal glucose homeostasis / MGI
- decreased circulating corticosterone level / MGI
- increased circulating alanine transaminase level / MGI
- increased liver weight / MGI
- liver fibrosis / MGI
- oxidative stress / MGI
- maternal effect / MGI
- increased hepatocyte apoptosis / MGI
- decreased lean body mass / MGI
- abnormal arteriole morphology / MGI
- abnormal retinal pigment epithelium morphology / MGI
- abnormal Bruch membrane morphology / MGI
- abnormal circulating amino acid level / MGI
- insulin resistance / MGI
- increased circulating glucose level / MGI
- abnormal choriocapillaris morphology / MGI
- abnormal short term spatial reference memory / MGI
- abnormal synaptic bouton morphology / MGI
- photoreceptor outer segment degeneration / MGI
- abnormal synapse morphology / MGI
- abnormal circulating LDL cholesterol level / MGI
- abnormal lipid homeostasis / MGI
- abnormal cholesterol homeostasis / MGI
- abnormal circulating protein level / MGI
MGI phenotypes (gene matching)
- abnormal microglial cell morphology / MGI
- abnormal circulating cholesterol level / MGI
- abnormal circulating LDL cholesterol level / MGI
- increased circulating LDL cholesterol level / MGI
- decreased circulating HDL cholesterol level / MGI
- abnormal triglyceride level / MGI
- alopecia / MGI
- abnormal liver physiology / MGI
- abnormal adrenal gland morphology / MGI
- abnormal hippocampus morphology / MGI
- abnormal CNS glial cell morphology / MGI
- scaly skin / MGI
- thick skin / MGI
- obese / MGI
- hyperactivity / MGI
- abnormal spatial learning / MGI
- increased circulating triglyceride level / MGI
- increased circulating free fatty acid level / MGI
- increased circulating HDL cholesterol level / MGI
- hyperglycemia / MGI
- liver inflammation / MGI
- abnormal glucose homeostasis / MGI
- increased circulating insulin level / MGI
- abnormal lipid homeostasis / MGI
- no abnormal phenotype detected / MGI
- abnormal astrocyte morphology / MGI
- hepatic steatosis / MGI
- decreased circulating triglyceride level / MGI
- decreased circulating corticosterone level / MGI
- gallstones / MGI
- increased circulating alanine transaminase level / MGI
- increased liver weight / MGI
- no phenotypic analysis / MGI
- retinal detachment / MGI
- amyloid beta deposits / MGI
- liver fibrosis / MGI
- oxidative stress / MGI
- maternal effect / MGI
- increased hepatocyte apoptosis / MGI
- abnormal circulating lipid level / MGI
- decreased lean body mass / MGI
- increased circulating VLDL triglyceride level / MGI
- increased cholesterol level / MGI
- abnormal arteriole morphology / MGI
- increased macrophage derived foam cell number / MGI
- increased circulating VLDL cholesterol level / MGI
- increased circulating cholesterol level / MGI
- decreased circulating cholesterol level / MGI
- abnormal retinal pigment epithelium morphology / MGI
- abnormal Bruch membrane morphology / MGI
- abnormal cholesterol homeostasis / MGI
- impaired glucose tolerance / MGI
- abnormal circulating amino acid level / MGI
- insulin resistance / MGI
- abnormal fat pad morphology / MGI
- atherosclerotic lesions / MGI
- increased susceptibility to atherosclerosis / MGI
- homeostasis/metabolism phenotype / MGI
- abnormal circulating protein level / MGI
- increased susceptibility to weight gain / MGI
- increased percent body fat/body weight / MGI
- increased circulating glucose level / MGI
- abnormal choriocapillaris morphology / MGI
- abnormal spatial working memory / MGI
- abnormal short term spatial reference memory / MGI
- increased circulating tumor necrosis factor level / MGI
- abnormal synaptic bouton morphology / MGI
- photoreceptor outer segment degeneration / MGI
- decreased circulating interleukin-10 level / MGI
- increased circulating interleukin-6 level / MGI
- increased circulating interleukin-1 beta level / MGI
- increased liver triglyceride level / MGI
- abnormal synapse morphology / MGI
- increased liver cholesterol level / MGI
- increased grip strength / MGI
- decreased susceptibility to weight gain / MGI
Literature references
- Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis.;Hermansson Andreas, Ketelhuth Daniel F J, Strodthoff Daniela, Wurm Marion, Hansson Emil M, Nicoletti Antonino, Paulsson-Berne Gabrielle, Hansson Göran K, ;2010;The Journal of experimental medicine;207;1081-93; 20439543
- Immunotherapy with tolerogenic apolipoprotein B-100-loaded dendritic cells attenuates atherosclerosis in hypercholesterolemic mice.;Hermansson Andreas, Johansson Daniel K, Ketelhuth Daniel F J, Andersson John, Zhou Xinghua, Hansson Göran K, ;2011;Circulation;123;1083-91; 21357823
- Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100.;Boren J, Lee I, Zhu W, Arnold K, Taylor S, Innerarity T L, ;1998;The Journal of clinical investigation;101;1084-93; 9486979
- Liver damage promotes pro-inflammatory T-cell responses against apolipoprotein B-100.;Plochg Bastian F J, Englert Hanna, Rangaswamy Chandini, Konrath Sandra, Malle Mandy, Lampalzer Sibylle, Beisel Claudia, Wollin Salma, Frye Maike, Aberle Jens, Kluwe Johannes, Renné Thomas, Mailer Reiner K, ;2022;Journal of internal medicine;291;648-664; 34914849
- Atheroprotective Immunity and Interleukin-10 Linked to Reduced Characteristics of Plaque Stability.;Yu Yinda, Lin Shiying, Pan Yueyun, He Ning, Wu Yanzhao, Ahmed Osman, Hedin Ulf, Karlsson Mikael C I, Li Nailin, Gisterå Anton, ;2025;JACC. Basic to translational science;10;101322; 40674844
Information on how we integrate external resources can be found here
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).
